A systematic review and meta-analysis of neuropathic pain associated with COVID-19
Type de matériel :
6
Background and objectiveNeuropathic pain is a complication of COVID-19 that has been occasionally reported and has received increased attention in the scientific literature. In this systematic review and meta-analysis, we aimed to provide information on the frequency of neuropathic pain associated with COVID-19.Databases and data treatmentWe systematically reviewed and analyzed literature regarding neuropathic pain associated with COVID-19. Literature searches were conducted in the PubMed, EMBASE, and Cochrane Library databases. We considered prospective and retrospective studies published up until September 2022 (limitations included English language, full-text publications, and studies including at least 10 patients). A random-effects meta-analysis was performed and heterogeneity and publication bias were assessed.ResultsWe identified 149 studies. We included 17 studies in the systematic review, and included 6 studies reporting the frequency of neuropathic pain in the acute/subacute phase of COVID-19 in the meta-analysis. The estimated frequency of neuropathic pain ranged between 0.4 and 25%. Forest plot analysis showed that the random effect overall frequency was 10% (95% CI: 5%–15%), with a high level of heterogeneity (Chi2 = 104; Tau2 = 0.004; df = 5; I2 = 95%; test for overall effect: Z = 3.584; p ConclusionsThe estimated frequency of neuropathic pain associated with COVID-19 should be interpreted with caution due to the high heterogeneity across studies and the lack of clear diagnostic criteria. Significance: Emerging evidence supports the development of neuropathic pain as a complication of COVID-19. However, longitudinal studies that enroll consecutive patients with COVID-19 and establish clear diagnostic criteria for neuropathic pain are needed to better assess the frequency of this condition.
Réseaux sociaux